CIK: 0001892134
Total reported value
$3.9B
Reporting period: 2026-03-31 · Number of holdings: 38
Frazier Life Sciences Management, L.P. disclosed 38 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $3.9B and a quarterly turnover rate of 31.5%.
Browse other institutions with $1B to $10B AUMBrowse other institutions starting with "F"
Frazier Life Sciences Management, L.P.'s disclosed holdings carry a Herfindahl concentration index of 0.082 — mathematically equivalent to about 12 equally-sized positions, well below its 38 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 1.48), with a handful of outsized bets alongside many smaller positions.
Recent activity leans toward adding more aggressively to already-large existing positions than to newly initiated ones (a 2.6 percentage-point tilt) — a pattern consistent with a momentum-following approach.
Sector classification currently covers about 15% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add ERAS
+8.6% $314.7M
Add MIRM
+13.0% $172.7M
Trim NAMS
0.0% -$52.0M
Trim PHAT
0.0% -$68.3M
Trim ARQT
0.0% -$54.1M
Trim MAZE
0.0% -$52.9M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MIRM | Mirum Pharmaceuticals INC | Stock-Other | 18.25% | +3.83% | +13.02% | |
| 2 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 13.96% | -2.00% | — | |
| 3 | ERAS | Erasca INC | Stock-Other | 10.27% | +8.00% | +8.56% | |
| 4 | BBIO | Bridgebio Pharma INC | Stock-Healthcare | 6.59% | -0.69% | -2.75% | |
| 5 | ARQT | Arcutis Biotherapeutics INC | Stock-Other | 5.99% | -1.71% | — | |
| 6 | MBX | Mbx Biosciences INC | Stock-Other | 5.11% | -0.53% | — | |
| 7 | PHAT | Phathom Pharmaceuticals INC | Stock-Other | 3.56% | -1.99% | — | |
| 8 | MAZE | Maze Therapeutics INC | Stock-Other | 3.51% | -1.57% | — | |
| 9 | KRYS | Krystal Biotech INC | Stock-Healthcare | 3.20% | -0.03% | -1.46% | |
| 10 | TRVI | Trevi Therapeutics INC | Stock-Other | 3.05% | -0.40% | -3.12% | |
| 11 | PVLA | Palvella Therapeutics INC | Stock-Other | 2.83% | +0.80% | +22.15% | |
| 12 | 4XC1 | Kalvista Pharmaceuticals INC | Stock-Other | 2.57% | +0.38% | -1.56% | |
| 13 | IRON | Disc Medicine INC | Stock-Other | 2.23% | -0.46% | +7.53% | |
| 14 | CYTK | Cytokinetics INC | Stock-Healthcare | 1.97% | +0.37% | +24.10% | |
| 15 | RVMD | Revolution Medicines INC | Stock-Healthcare | 1.69% | -0.02% | -15.27% | |
| 16 | DYN | Dyne Therapeutics INC | Stock-Other | 1.47% | -0.19% | — | |
| 17 | SVRA | Savara INC | Stock-Other | 1.37% | -0.23% | -1.43% | |
| 18 | TARS | Tarsus Pharmaceuticals INC | Stock-Other | 1.32% | -0.28% | — | |
| 19 | VOR | Vor Biopharma INC | Stock-Other | 1.17% | +0.28% | — | |
| 20 | AGIO | Agios Pharmaceuticals INC | Stock-Other | 1.09% | +0.15% | -1.85% | |
| 21 | BCRX | Biocryst Pharmaceuticals INC | Stock-Other | 0.98% | +0.98% | NEW | |
| 22 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 0.92% | +0.02% | — | |
| 23 | AURA | Aura Biosciences INC | Stock-Other | 0.88% | +0.13% | — | |
| 24 | ACAD | Acadia Pharmaceuticals INC | Stock-Healthcare | 0.82% | -0.11% | +10.87% | |
| 25 | ASND | Ascendis Pharma A/S | Stock-Other | 0.78% | +0.02% | — | |
| 26 | LXEO | Lexeo Therapeutics INC | Stock-Other | 0.65% | -0.53% | — | |
| 27 | ALKS | Alkermes plc | Stock-Healthcare | 0.64% | +0.11% | — | |
| 28 | ACRS | Aclaris Therapeutics INC | Stock-Other | 0.48% | +0.48% | NEW | |
| 29 | GLUE | Monte Rosa Therapeutics INC | Stock-Other | 0.42% | +0.42% | NEW | |
| 30 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.38% | +0.02% | +25.99% | |
| 31 | MNKD | Mannkind CORP | Stock-Other | 0.37% | -0.27% | +39.65% | |
| 32 | VALN | Valneva Se - Adr | Stock-Other | 0.37% | -0.17% | — | |
| 33 | EOLS | Evolus INC | Stock-Other | 0.28% | -0.19% | — | |
| 34 | ✓ | Newamsterdam Pharma Company | Stock-Other | 0.26% | -0.05% | — | |
| 35 | ALLO | Allogene Therapeutics INC | Stock-Other | 0.24% | +0.10% | -1.86% | |
| 36 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.16% | -0.09% | -3.79% | |
| 37 | IBIO | Ibio INC | Stock-Other | 0.10% | — | — | |
| 38 | XLO | Xilio Therapeutics INC | Stock-Other | 0.09% | +0.09% | NEW |
Performance for Q3 2026
+23.2%
Performance Last 4 Quarters
+111.9%
Based on 83% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 38 | $3.9B | 31 | |
| 2025-12-31 | 40 | $3.7B | 43 | |
| 2025-09-30 | 47 | $3.3B | 51 | |
| 2025-06-30 | 49 | $2.5B | 0 | |
| 2025-03-31 | 47 | $2.2B | 0 | |
| 2024-12-31 | 50 | $2.4B | 0 | |
| 2024-09-30 | 53 | $2.5B | 0 | |
| 2024-06-30 | 49 | $2.1B | 0 | |
| 2024-03-31 | 50 | $2.4B | 0 | |
| 2023-12-31 | 49 | $1.9B | 0 | |
| 2023-09-30 | 52 | $1.5B | 0 | |
| 2023-06-30 | 48 | $1.7B | 0 | |
| 2023-03-31 | 49 | $1.4B | 0 | |
| 2022-12-31 | 44 | $1.6B | 0 | |
| 2022-09-30 | 43 | $1.3B | 0 | |
| 2022-06-30 | 41 | $1.1B | 0 | |
| 2022-03-31 | 42 | $1.2B | 0 |
Frazier Life Sciences Management, L.P.'s most significant position changes for 2026-03-31: Sold out: Avidity Biosciences INC (RNAGBP); Sold out: Abivax Sa-adr (ABVX); New buy: Biocryst Pharmaceuticals INC (BCRX); Sold out: Rapt Therapeutics INC (RAPT); New buy: Aclaris Therapeutics INC (ACRS).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ERAS | Erasca INC | +8% | +8.56% | Add |
| 2 | MIRM | Mirum Pharmaceuticals INC | +3.8% | +13.02% | Add |
| 3 | PVLA | Palvella Therapeutics INC | +0.8% | +22.15% | Add |
| 4 | 4XC1 | Kalvista Pharmaceuticals INC | +0.4% | -1.56% | Trim |
| 5 | CYTK | Cytokinetics INC | +0.4% | +24.10% | Add |
| 6 | VOR | Vor Biopharma INC | +0.3% | — | Unchanged |
| 7 | AGIO | Agios Pharmaceuticals INC | +0.2% | -1.85% | Trim |
| 8 | AURA | Aura Biosciences INC | +0.1% | — | Unchanged |
| 9 | ALKS | Alkermes plc | +0.1% | — | Unchanged |
| 10 | ALLO | Allogene Therapeutics INC | +0.1% | -1.86% | Trim |
| 11 | ZLAB | Zai Lab Ltd-adr | 0% | — | Unchanged |
| 12 | ASND | Ascendis Pharma A/S | 0% | — | Unchanged |
| 13 | IMCR | Immunocore Holdings Plc-adr | 0% | +25.99% | Add |
| 14 | IBIO | Ibio INC | — | — | Unchanged |
| 15 | RVMD | Revolution Medicines INC | 0% | -15.27% | Trim |
| 16 | KRYS | Krystal Biotech INC | 0% | -1.46% | Trim |
| 17 | ✓ | Newamsterdam Pharma Company | -0.1% | — | Unchanged |
| 18 | AUTL | Autolus Therapeutics PLC | -0.1% | -3.79% | Trim |
| 19 | ACAD | Acadia Pharmaceuticals INC | -0.1% | +10.87% | Add |
| 20 | VALN | Valneva Se - Adr | -0.2% | — | Unchanged |
| 21 | EOLS | Evolus INC | -0.2% | — | Unchanged |
| 22 | DYN | Dyne Therapeutics INC | -0.2% | — | Unchanged |
| 23 | SVRA | Savara INC | -0.2% | -1.43% | Trim |
| 24 | MNKD | Mannkind CORP | -0.3% | +39.65% | Add |
| 25 | TARS | Tarsus Pharmaceuticals INC | -0.3% | — | Unchanged |
| 26 | TRVI | Trevi Therapeutics INC | -0.4% | -3.12% | Trim |
| 27 | IRON | Disc Medicine INC | -0.5% | +7.53% | Add |
| 28 | LXEO | Lexeo Therapeutics INC | -0.5% | — | Unchanged |
| 29 | MBX | Mbx Biosciences INC | -0.5% | — | Unchanged |
| 30 | BBIO | Bridgebio Pharma INC | -0.7% | -2.75% | Trim |
| 31 | MAZE | Maze Therapeutics INC | -1.6% | — | Unchanged |
| 32 | ARQT | Arcutis Biotherapeutics INC | -1.7% | — | Unchanged |
| 33 | PHAT | Phathom Pharmaceuticals INC | -2% | — | Unchanged |
| 34 | NAMS | NewAmsterdam Pharma Company N.V. | -2% | — | Unchanged |
| 35 | RNAGBP | Avidity Biosciences INC | — | EXIT | Sold out |
| 36 | ABVX | Abivax Sa-adr | — | EXIT | Sold out |
| 37 | BCRX | Biocryst Pharmaceuticals INC | — | NEW | New buy |
| 38 | RAPT | Rapt Therapeutics INC | — | EXIT | Sold out |
| 39 | ACRS | Aclaris Therapeutics INC | — | NEW | New buy |
| 40 | GLUE | Monte Rosa Therapeutics INC | — | NEW | New buy |
| 41 | TVTX | Travere Therapeutics INC | — | EXIT | Sold out |
| 42 | DSGN | Design Therapeutics INC | — | EXIT | Sold out |
| 43 | ✓ | Xilio Therapeutics INC | — | EXIT | Sold out |
| 44 | XLO | Xilio Therapeutics INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-13 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-18 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-15 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-15 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-07 | Amendment | View on EDGAR |
| 2022-12-31 | 2023-02-03 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-10 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-16 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0000315498
Total reported value
$3.9B
602 stks
2022-12-31
Stale — no recent filing
AUM within 0.1% of this institution
CIK 0001848138
Total reported value
$3.9B
35 stks
2026-03-31
AUM within 0.2% of this institution
CIK 0001142206
Total reported value
$3.9B
1 stks
2026-03-31
AUM within 0.2% of this institution
Institutions with overlapping top holdings
CIK 0001158202
Total reported value
$1.3B
172 stks
2026-03-31
1 of the top 5 holdings overlap, including Mirum Pharmaceuticals INC
CIK 0001232621
Total reported value
$2.0B
51 stks
2026-03-31
1 of the top 5 holdings overlap, including Mirum Pharmaceuticals INC
CIK 0001274403
Total reported value
$677.1M
10 stks
2026-03-31
1 of the top 5 holdings overlap, including Erasca INC